Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Gains from Sales and Divestitures (2014 - 2025)

Kura Oncology (KURA) reported Gains from Sales and Divestitures of $401000.0 for Q4 2025, up 208.46% on a QoQ basis from $130000.0 in Q4 2018.

Kura Oncology (KURA) has 6 years of Gains from Sales and Divestitures data on file, last reported at $401000.0 in Q4 2025.

  • Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $401000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $401000.0 (changed N/A YoY) and the FY2025 annual result came in at $401000.0, changed N/A from the prior year.
  • Gains from Sales and Divestitures grew to $401000.0 in Q4 2025 per KURA's latest filing, from $130000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $401000.0 in Q4 2025 and bottomed at $401000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 401,000.00
Dec 31, 2025 401,000.00
Dec 31, 2018 130,000.00
Dec 31, 2018 130,000.00
Dec 31, 2017 1.00 Mn
Dec 31, 2017 1.00 Mn
Dec 31, 2016 1.02 Mn
Dec 31, 2016 1.02 Mn
Dec 31, 2015 1.04 Mn
Dec 31, 2015 1.04 Mn
Sep 30, 2015 194,842.00
Sep 30, 2015 194,842.00
Jun 30, 2015 235,103.00
Jun 30, 2015 235,103.00
Mar 31, 2015 342.00
Mar 31, 2015 342.00
Dec 31, 2014 411,000.00
Dec 31, 2014 411,000.00